Urva S, Coskun T, Loh MT, Du Y, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022 Oct 27. pii: S0140-6736(22)02033.
PMID: 36354040